Atsena Therapeutics announced in a press release that the FDA granted its gene therapy product candidate, ATSN-201, the regenerative medicine advanced therapy (RMAT) designation to treat X-linked ...

Pykus Therapeutics announced it has completed enrollment in its pilot study, PYK-2101-RD00, evaluating PYK-2101, a focal hydrogel retinal sealant, in patients undergoing surgery for detached retina.

A new study found that an artificial intelligence reading label system improves ophthalmologists' diagnostic accuracy for retinal diseases and could be valuable in future medical education. A new ...

Opus Genetics issued a press release today announcing the 1-month open-label phase 1/2 results from the first pediatric patients treated with its investigational gene therapy candidate, OPGx-LCA5, for ...

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely monitored for its onset. Taiwanese investigators found in their cohort ...

As part of its five-year strategic plan, Prevent Blindness has promoted five individuals to further the organization’s mission. Prevent Blindness has promoted five leaders to further its efforts and ...

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME). Vantage ...

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Aviceda Therapeutics recently appointed Jeffrey Nau, PhD, MMS, as chief executive officer. Nau comes to Aviceda with more than 20 years of experience leading and expanding biotechnology and ...

Novelty Nobility, a Korean antibody drug discovery company, recently announced it has been selected to join JLABS Korea. 1 JLABS, part of Johnson & Johnson’s global incubator network, supports ...